FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076862565> ?p ?o ?g. }

• W2076862565 endingPage "156" @default.
• W2076862565 startingPage "137" @default.
• W2076862565 abstract "Cardiovascular Drug ReviewsVolume 15, Issue 2 p. 137-156 Free Access Pharmacology of Azimilide Dihydrochloride (NE-10064), A Class III Antiarrhythmic Agent Joseph J. Salata, Joseph J. Salata Merck Research Laboratories, West Point, PA 19486-0004, USASearch for more papers by this authorRobert R. Brooks, Corresponding Author Robert R. Brooks Procter & Gamble Pharmaceuticals, Norwich, NY 13815-0191, USAAddress correspondence and reprint requests to Dr. R. R. Brooks at Drug Safety Assessment, Procter & Gamble Pharmaceuticals, P.O. Box 191, Norwich, NY 13815-0191. Fax: 607-335-2009.Search for more papers by this author Joseph J. Salata, Joseph J. Salata Merck Research Laboratories, West Point, PA 19486-0004, USASearch for more papers by this authorRobert R. Brooks, Corresponding Author Robert R. Brooks Procter & Gamble Pharmaceuticals, Norwich, NY 13815-0191, USAAddress correspondence and reprint requests to Dr. R. R. Brooks at Drug Safety Assessment, Procter & Gamble Pharmaceuticals, P.O. Box 191, Norwich, NY 13815-0191. Fax: 607-335-2009.Search for more papers by this author First published: 02 April 2007 https://doi.org/10.1111/j.1527-3466.1997.tb00328.xCitations: 56AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Bahinski A, Anderson D, Oliva C, Tatla DS. Rate-dependent prolongation of cardiac action potential duration by class III drugs: Correlation with specificity of IKs blockade. PACE 1996; 19: 644. 2 Bahinski A, Claycomb WC, Izzo NJ. Identification of a cardiac-specific delayed rectifier K+ current in a novel immortalized murine cardiac cell line (HL-1). Pharmacologist 1997; 39: 57. 3 Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 1993; 22: 810– 818. 4 Brandt MA, Maynard AE. NE-10064 exhibits class III antiarrhythmic effects after intravenous or oral administration in conscious dogs. FASEB J 1994; 8: A7. 5 Bril A, Dusseau C, Forest M, Cheval B, Faivre J. Comparative effects of BRL-32872 and azimilide on action potential duration in guinea pig isolated papillary muscle. FASEB J 1996; 10: A65. 6 Brooks RR, Butterfield JL. The class III antiarrhythmic NE-10064 increases QTc interval with minor hemodynamic effects in anesthetized dogs. Can J Physiol Pharmacol (Suppl 1) 1994; 72: 79. 7 Brooks RR, Carpenter JF, Jones SM, Gregory CM. Effects of dantrolene sodium in rodent models of cardiac arrhythmia. Eur J Pharmacol 1989; 164: 521– 530. 8 Brooks RR, Carpenter JF, Miller KE, Maynard AE. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Proc Soc Exp Biol Med 1996; 212: 84– 93. 9 Busch AE, Herzer T, Takumi T, Krippeit-Drews P, Waldegger S, Lang F. Blockade of human IsK channels expressed in Xenopus oöcytes by the novel class III antiarrhythmic NE-10064. Eur J Pharmacol 1994; 264: 33– 37. 10 Busch AE, Malloy K, Groh WJ, Varnum MD, Adelman JP, Maylie J. The novel class III antiarrhythmics NE-10064 and NE-10133 inhibit IsK channels expressed in Xenopus oocytes and IKs in guinea pig cardiac myocytes. Biochem Biophys Res Commun 1994; 202: 265– 270. 11 Conder ML, Hess TA, Smith MA, D'Alonzo AJ, McCullough JR. The effects of NE-10064 on cardiac sodium channels. FASEB J 1994; 8: A609. 12 Conder ML, Smith MA, Atwal KS, McCullough JR. Effects of NE-10064 on K+ currents in cardiac cells. Biophys J 1994; 66: A326. 13 Davies MP, Freeman LC, Kass RS. Dual actions of the novel class III antiarrhythmic drug NE-10064 on delayed potassium channel currents in the guinea pig ventricular and sinoatrial node cells. J Pharmacol Exp Ther 1996; 276: 1149– 1154. 14 Drexler AP, Al-Khalidi H, Maynard AE, et al. Comparison of azimilide dihydrochloride (NE-10064) and selected class III antiarrhythmic agents in a rabbit model of proarrhythmia. FASEB J 1996; 10: A33. 15 Drexler AP, Maynard AE, Brooks RR, Oliva C, Kostreva DR. Azimilide dihydrochloride (NE-10064) prolongs the QTc interval in rabbits, a species lacking ventricular slow K+ current (IKs). Biophys J 1995; 68: A111. 16 Drexler AP, Micklas JM, Brooks RR. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. J Cardiovasc Pharmacol 1996; 28: 848– 855. 17 Eigenberger B, Suessbrich H, Salata JJ, Jurkiewicz NK, Lang F, Busch AE. Characterization of the blockade of HERG channel blockade by the class III antiarrhythmic azimilide: Mechanism and specificity. Pflügers Arch-Eur J Physiol 1997; 433: R88. 18 Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995; 26: 259– 271. 19 Gintant GA. Paradoxical effect of combined administration of class III agents on the canine ventricular action potential. Circulation 1996; 94: 1– 160. 20 Gintant GA. Pharmacologie identification of IKs in canine ventricular myocytes: Effects of NE-10064 (azimilide). Circulation 1994; 90: 1– 146. 21 Gintant GA. Two components of delayed rectifier current in canine atrium and ventricle—does I-KS play a role in the reverse rate dependence of class III agents Circ Res 1996; 78: 26– 37. 22 Groh WJ, Gibson KJ, Maylie JG. Azimilide (NE-10064) prolongs action potential duration in a reverse rate-dependent manner in guinea pig ventricular muscle. PACE 1995; 18: 853. 23 Groh WJ, Maylie JG. Efficacy of NE-10064 in maintaining repolarizing current block after d, l-sotalol and isoproterenol. PACE 1994; 17: 755. 24 Harrison DC. Current classification of antiarrhythmic drues as a guide to their rational clinical use. Drugs 1986; 31: 93– 95. 25 Herzer T, Wagner CA, Waldegger S, Lang F, Busch AE. Effects of channel modulation and pH on IsK inhibition by the novel class III antiarrhythmic azimilide (NE-10064). Eur J Pharmacol 1995; 291: 205– 208. 26 Jackson KN, Lowe ER, Benn DR, Drexler AP, Kostreva DR, Mittelstadt SW. Effect of azimilide on left ventricular function in anesthetized dogs during ischemia. FASEB J 1996; 10: A429. 27 Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methane-sulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993; 72: 75– 83. 28 Kulbertus HE. Antiarrhythmic treatment of atrial arrhythmias. J Cardiovasc Pharmacol 1991; 17: S32– S35. 29 Lamorgese M, Kirian M, van Wagoner DR. Azimilide (NE-10064) blocks outward K+ currents in human atrial and ventricular myocytes. Circulation (Suppl 8) 1995; 92: 1– 575. 30 Lascault G, Asta J, Cameron D, Waxman MB. Electrophysiologic effect of sodium dantrolene on cardiac action potential. Circulation 1982; 66: 11– 294. 31 Lavine SJ, Prcevski P. Comparison of hemodynamic effects of 2 type III antiarrhythmic agents in dogs with chronic ischemic left ventricular dysfunction. J Invest Med 1996; 44: 211A. 32 Maynard AE, Benn DR, Lowe ER, Kostreva DR, Mittelstadt SW. Beta-adrenergic effects of intravenous azimilide in the pentobarbital-anesthetized rat. FASEB J 1996; 10: A427. 33 McIntosh MA, Tanira M, Pacini D, Kane KA. Comparison of the electrophysiological effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischemia. J Cardiovasc Pharmacol 1994; 23: 653– 657. 34 Miller KE, Carpenter JF, Brooks RR. An in vitro guinea pig heart model providing contractility and electrophysiology data on antiarrhythmic compounds. Pharmacologist 1988; 30: A178. 35 Miller KE, Carpenter JF, Brooks RR. Beta-adrenergic effects of the class III antiarrhythmic agent NE-10064 in the isolated perfused guinea pig heart. FASEB J 1993; 7: A108. 36 Nattel S, Liu L, St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Concentration-dependence and comparison with the IKr blocker dofetilide. J Am Coll Cardiol 1997 (in press). 37 Pinto J, Boyden P, Wit A, Brooks R. The effects of a class III antiarrhythmic agent NE-10064 which blocks the slowly-activating delayed rectifier current (IKs) on canine atrial flutter. PACE 1994; 17: 777. 38 Podrid PJ. Safety and toxicity of antiarrhythmic drug therapy: Benefit versus risk. J Cardiovasc Pharmacol (Suppl 6) 1991; 17: S65– S73. 39 Poole JE, Bardy GH. Sudden cardiac death. In: DP Zipes, J Jalife, eds. Cardiac Electrophysiology from Cell to Bedside. Philadelphia : W.B. Saunders Company, 1995: 812– 832. 40 Pong SF, Kinney CM, Moorehead TJ. Binding profiles of NE-10064, a novel class III antiarrhythmic agent, to rat brain receptors. FASEB J 1993; 7: A474. 41 Qi X, Newman D, Dorian P. Azimilide (NE-10064) increases coherence during ventricular fibrillation in the anesthetized dog. PACE 1996; 19: 730. 42 Qi X, Newman D, Dorian P. Class III effect of azimilide (NE-10064): Prevention of reverse use-dependence in open-chest dogs. PACE 1996; 19: 692. 43 Qi X, Newman D, Dorian P. Class III effect of azimilide (NE-10064): Prevention of reverse use-dependence on monophasic action potential duration in open-chest dogs. Circ Res 1997 (in press). 44 Reiser HJ, Sullivan ME. Antiarrhythmic drug therapy: New drugs and changing concepts. Fed Proc 1986; 45: 2206– 2212. 45 Restivo M, Hegazy M, Caref EB, et al. Termination and prevention of circus movement atrial flutter in the sterile pericarditis model by a novel type III agent, azimilide (NE-10064). Circulation 1994; 90: 1– 413. 46 Restivo M, Hegazy M, El-Hamamy M, et al. Antiarrhythmic efficacy of azimilide dihydrochloride on functional circus movement atrial flutter in the canine right atrial enlargement model. PACE 1996; 19: 664. 47 Restivo M, Yin H, Caref EB, Levin R, Assadi MA, Brooks RR. Selective effect of class III antiarrhythmic agents on refractoriness determines efficacy in post infarction reentrant ventricular tachyarrhythmias (VT). Circulation 1996; 94: 1– 161. 48 Rosen MR, Strauss HC, Janse MJ. The classification of antiarrhythmic drugs. In: DP Zipes, J Jalife, eds. Cardiac Electrophysiology from Cell to Bedside. Philadelphia : W.B. Saunders Company, 1995: 1277– 1286. 49 Salata JJ, Jalife J. Effects of dantrolene sodium on the electrophysiological properties of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1982; 220: 157– 166. 50 Salata JJ, Wasserstrom JA, Jalife J. Dantrolene sodium: Effects on isolated cardiac tissues. J Mol Cell Cardiol 1983; 15: 233– 243. 51 Sanderson J. The SWORD of Damocles. Lancet 1996; 348: 2– 3. 52 Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81: 299– 307. 53 Sanguinetti MC, Jurkiewicz NK. Delayed rectifier outward K+ current is composed of two currents in guinea pig atrial cells. Am J Physiol 1991; 260: H393– H399. 54 Smith MA, Conder ML, Atwal KS, McCullough JR. Effects of clofilium and NE-10064 on IKs, the slow component of the cardiac delayed rectifier. Biophys J 1994; 66: A209. 55 Spector PS, Curran ME, Keating MT, Sanguinetti MC. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Circ Res 1996; 78: 499– 503. 56 Tatla DS, David BC, Malloy KJ. Moorehead TJ. In vitro electrophysiology of NE-10064, a novel and highly selective class III antiarrhythmic agent. FASEB J 1993; 7: A107. 57 Vanoli E, Hull SSJ, Jackman WM, Bussey JD, Foreman RD, Schwartz PJ. Combined blockade of IKr and IKs enhances the arrhythmogenic effect of sympathetic stimulation. Circulation 1996; 94: 1– 160. 58 Vanoli E, Hull SSJ, Adamson PB, Foreman RD, Schwartz PJ. K+ channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. J Cardiovasc Pharmacol 1995; 26: 847– 854. 59 Wade-Whittaker F, Sansone DL, Erickson BK. Rate-dependent effects of azimilide (AZ) and dofetilide (DO) on cardiac refractoriness in the ferret. FASEB J 1996; 10: A64. 60 Waldo AL, Camm AJ, de Ruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 236: 7– 12. 61 Yang T, Wathen MS, Felipe A, Tamkun MM, Snyders DJ, Roden DM. K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ Res 1994; 75: 870– 878. 62 Yao J, Tseng G. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: Dependence on blockade of K, Ca, and Na channels. J Cardiovasc Electrophysiol 1997 (in press). 63 Yao J, Tseng G. Effects of azimilide (NE-10064) on cardiac K channels. J Am Coll Cardiol 1995; Special Issue: 176A. 64 Yu C, Pelosi SS, Calcagno MA (inventors); Norwich Eaton Pharmaceuticals (assignee). 4-Oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents. U.S. Pat. 5,462,940, 1995. 65 Zhang ZH, Boutjdir M, Brooks RR, El-Sherif N. Mechanisms of use-independent effect of a novel class III drug, azimilide: Characterization of the effects on repolarization currents in guinea pig and rat ventricular myocytes. Circ Res 1997 (in press). Citing Literature Volume15, Issue2June 1997Pages 137-156 ReferencesRelatedInformation" @default.
• W2076862565 created "2016-06-24" @default.
• W2076862565 creator A5016533841 @default.
• W2076862565 creator A5036316377 @default.
• W2076862565 date "1997-06-01" @default.
• W2076862565 modified "2023-10-16" @default.
• W2076862565 title "Pharmacology of Azimilide Dihydrochloride (NE-10064), A Class III Antiarrhythmic Agent" @default.
• W2076862565 cites W1890151633 @default.
• W2076862565 cites W1964565720 @default.
• W2076862565 cites W1968098810 @default.
• W2076862565 cites W1981011106 @default.
• W2076862565 cites W1983136738 @default.
• W2076862565 cites W1985089609 @default.
• W2076862565 cites W1993543392 @default.
• W2076862565 cites W2006883095 @default.
• W2076862565 cites W2007249629 @default.
• W2076862565 cites W2011432387 @default.
• W2076862565 cites W2013603594 @default.
• W2076862565 cites W2025521414 @default.
• W2076862565 cites W2049858915 @default.
• W2076862565 cites W2059076978 @default.
• W2076862565 cites W2065568826 @default.
• W2076862565 cites W2065880668 @default.
• W2076862565 cites W2074278413 @default.
• W2076862565 cites W2074285616 @default.
• W2076862565 cites W2076910520 @default.
• W2076862565 cites W2090007860 @default.
• W2076862565 cites W2099086672 @default.
• W2076862565 cites W2143518969 @default.
• W2076862565 cites W2168806904 @default.
• W2076862565 cites W2319484146 @default.
• W2076862565 cites W2331920186 @default.
• W2076862565 cites W2980486406 @default.
• W2076862565 cites W4239707521 @default.
• W2076862565 cites W4240306269 @default.
• W2076862565 cites W4255064414 @default.
• W2076862565 cites W4297902066 @default.
• W2076862565 cites W4376463428 @default.
• W2076862565 doi "https://doi.org/10.1111/j.1527-3466.1997.tb00328.x" @default.
• W2076862565 hasPublicationYear "1997" @default.
• W2076862565 type Work @default.
• W2076862565 sameAs 2076862565 @default.
• W2076862565 citedByCount "67" @default.
• W2076862565 countsByYear W20768625652013 @default.
• W2076862565 countsByYear W20768625652021 @default.
• W2076862565 crossrefType "journal-article" @default.
• W2076862565 hasAuthorship W2076862565A5016533841 @default.
• W2076862565 hasAuthorship W2076862565A5036316377 @default.
• W2076862565 hasBestOaLocation W20768625651 @default.
• W2076862565 hasConcept C126322002 @default.
• W2076862565 hasConcept C185592680 @default.
• W2076862565 hasConcept C2778131192 @default.
• W2076862565 hasConcept C2780074459 @default.
• W2076862565 hasConcept C42219234 @default.
• W2076862565 hasConcept C71924100 @default.
• W2076862565 hasConcept C98274493 @default.
• W2076862565 hasConceptScore W2076862565C126322002 @default.
• W2076862565 hasConceptScore W2076862565C185592680 @default.
• W2076862565 hasConceptScore W2076862565C2778131192 @default.
• W2076862565 hasConceptScore W2076862565C2780074459 @default.
• W2076862565 hasConceptScore W2076862565C42219234 @default.
• W2076862565 hasConceptScore W2076862565C71924100 @default.
• W2076862565 hasConceptScore W2076862565C98274493 @default.
• W2076862565 hasIssue "2" @default.
• W2076862565 hasLocation W20768625651 @default.
• W2076862565 hasOpenAccess W2076862565 @default.
• W2076862565 hasPrimaryLocation W20768625651 @default.
• W2076862565 hasRelatedWork W1531601525 @default.
• W2076862565 hasRelatedWork W2384464875 @default.
• W2076862565 hasRelatedWork W2606230654 @default.
• W2076862565 hasRelatedWork W2607424097 @default.
• W2076862565 hasRelatedWork W2748952813 @default.
• W2076862565 hasRelatedWork W2899084033 @default.
• W2076862565 hasRelatedWork W2948807893 @default.
• W2076862565 hasRelatedWork W3031052312 @default.
• W2076862565 hasRelatedWork W4387497383 @default.
• W2076862565 hasRelatedWork W2778153218 @default.
• W2076862565 hasVolume "15" @default.
• W2076862565 isParatext "false" @default.
• W2076862565 isRetracted "false" @default.
• W2076862565 magId "2076862565" @default.
• W2076862565 workType "article" @default.